image credit: Piqsels

FDA grants emergency authorisation to Lilly’s COVID-19 antibody

November 11, 2020


Bamlanivimab is now available under emergency use for the treatment of mild to moderate COVID-19 in adults and paediatric patients 12 years and older who are at high risk of progressing to severe COVID-19 and/or hospitalisation.

In a statement, Lilly said that bamlanivimab should be administered as soon as possible after a positive COVID-19 test and within ten days of symptom onset.

The emergency approval is supported by data from Lilly’s BLAZE-1 study – a phase II study in patients with recently diagnosed mild to moderate COVID-19 in the outpatient setting.

Read More on Pharma Times